Key facts
- It has raised $41.0M; the latest was Grant ($1.0M) in Oct 2024.
- Notable investors include National Institutes of Health, SV Health Investors, FemHealth Ventures, Schooner Capital, Sparta Group — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Brixton Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Brixton Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brixton Biosciences
Developer of a biomedical neuromodulation therapy designed to sustain pain relief and support mobility. The company offers a proprietary neural cooling implant technology, featuring minimally invasive delivery, long-duration effects, and academic validation, enabling patients with chronic or acute musculoskeletal pain to regain function and reduce discomfort.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Website
- brixtonbio.com/
- Ownership
- Privately Held (backing)
Brixton Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brixton Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brixton Biosciences in its N-PORT filings yet. We sweep new filings monthly.